OverviewSuggest Edit
Daiichi Sankyo (第一三共株式会社) is a developer of pharmaceutical products. It engages in 4 businesses: the Innovative Pharmaceutical Business, the Generic Business, the Vaccine business, and the OTC-related business. The Innovative Pharmaceutical Business delivers a range of pharmaceuticals to patients ranging from the anticoagulant LIXIANA and other products in the primary care area to oncology products, among others, in the specialty care area. The Generic Business offers authorized generics (AG), or a new standard for generics featuring formulation, labelling, and packaging innovations that are easy to swallow but hard to swallow accidentally. The Vaccine business specializes in vaccines to prevent infectious diseases and develops a 3-valent combination vaccine containing three live attenuated viruses of measles, mumps, and rubella (MMR vaccine). The OTC-related business offers OTC drugs and a range of products including skincare cosmetics and oral care products.
| Type | Public | |
| Founded | 2005 | |
| HQ | Tokyo, JP | Map |
| Website | daiichisankyo.com | |
| Employee Ratings | More |
Recent NewsAll News
- $81 Billion Worldwide Musculoskeletal Disorders Drugs Industry to 2030 - Featuring Pfizer, Abbott Laboratories and Daiichi Sankyo Among Others
- Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics
- Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
- Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal
Key People/Management at Daiichi Sankyo
Sunao Manabe
President and CEO
Satoru Kimura
Head of Japan Business Unit
Masahiko Ohtsuki
Head of Digital Transformation Management Div.
Shoji Hirashima
Head of Corporate Strategy Div.
Hiroyuki Okuzawa
Head of Corporate Planning & Management Div., CFO
Hironobu Furuta
Head of Corporate Affairs Div.
Daiichi Sankyo Office Locations
Daiichi Sankyo has offices in Tokyo, Chiba, Chiyoda, Chuo City and in 39 other locations
Tokyo, JP (HQ)
3-5-1, Nihonbashi, Honcho, Chuo-ku
Chiba, JP
2-6-1, Nakase, Mihama-ku
Chiyoda, JP
2716-1, Aza Kurakake, Oaza Akaiwa
Chuo City, JP
Nihonbashi Building, 3-14-10, Nihonbashi, Chuo-ku
Fukuoka, JP
2-10-1, Hakata Eki Higashi, Hakata
Hiratsuka, JP
1-12-1, Shinomiya
Daiichi Sankyo Financials and Metrics
Daiichi Sankyo Revenue
Daiichi Sankyo's revenue was reported to be ¥962.52 b in FY, 2021
| JPY | |
|---|---|
Revenue (Q3, 2022) | 281.0b |
Gross profit (Q3, 2022) | 203.3b |
Net income (Q3, 2022) | 31.9b |
EBITDA (Q3, 2022) | 53.3b |
EBIT (Q3, 2022) | 39.1b |
Market capitalization (12-May-2022) | 5.7t |
Closing stock price (12-May-2022) | 3.2k |
Cash (31-Dec-2021) | 577.3b |
EV | 5.3t |
Daiichi Sankyo's current market capitalization is ¥5.7 t.
Annual
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 960.2b | 929.7b | 981.8b | 962.5b |
Cost of goods sold | (299.3b) | (318.4b) | (290.6b) | (280.9b) |
Gross profit | 660.9b | 611.3b | 691.2b | 681.6b |
R&D expense | (236.0b) | (203.7b) | (197.5b) | (227.4b) |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 225.7b | 221.1b | 256.2b | 249.2b | 230.3b | 277.5b | 236.9b | 243.2b | 258.6b | 264.1b | 265.9b | 281.0b |
Cost of goods sold | (73.5b) | (70.5b) | (86.6b) | (75.0b) | (75.8b) | (66.4b) | (68.1b) | (72.0b) | (73.4b) | (70.5b) | (73.1b) | (77.7b) |
Gross profit | 152.2b | 150.6b | 169.7b | 174.3b | 154.6b | 211.1b | 168.9b | 171.2b | 185.2b | 193.6b | 192.8b | 203.3b |
R&D expense | (45.5b) | (48.2b) | (48.9b) | (41.2b) | (44.7b) | (51.1b) | (48.8b) | (55.7b) | (59.1b) | (54.0b) | (55.0b) | (60.1b) |
Annual
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 258.2b | 154.9b | 280.4b | 294.8b |
Accounts Receivable | 210.8b | 360.4b | 282.5b | 201.0b |
Inventories | 172.6b | 176.1b | 173.4b | 200.9b |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 294.0b | 236.9b | 239.2b | 260.9b | 297.6b | 326.4b | 382.1b | 451.3b | 520.1b | 352.3b | 550.1b | 577.3b |
Accounts Receivable | 230.1b | 270.8b | 305.7b | 356.8b | 342.5b | 351.9b | 243.9b | 252.8b | 263.4b | 258.1b | 276.5b | 282.9b |
Inventories | 184.1b | 186.6b | 177.6b | 186.0b | 177.4b | 172.7b | 183.7b | 183.3b | 183.9b | 211.8b | 210.0b | 211.6b |
Annual
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 81.0b | 85.8b | 141.2b | 74.1b |
Depreciation and Amortization | 46.7b | 46.2b | 52.6b | 57.4b |
Inventories | (19.4b) | (4.0b) | (7.4b) | (21.2b) |
Accounts Payable | 238.0m | 60.4b | (44.7b) | 23.9b |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 29.6b | 58.6b | 98.0b | 57.1b | 87.0b | 160.0b | 41.4b | 67.0b | 99.6b | 47.1b | 86.0b | 125.9b |
Depreciation and Amortization | 11.2b | 22.6b | 34.3b | 12.9b | 26.4b | 39.2b | 14.1b | 28.5b | 42.9b | 14.7b | 29.0b | 43.2b |
Inventories | (11.1b) | (12.1b) | (5.0b) | (12.5b) | (11.7b) | (4.9b) | (10.4b) | (10.2b) | (11.2b) | (10.1b) | (7.7b) | (6.0b) |
Accounts Payable | (27.4b) | 3.8b | 8.2b | (23.9b) | (59.0b) | (85.5b) | (30.3b) | (22.0b) | (19.1b) | (33.9b) | (33.0b) | (23.4b) |
| JPY | FY, 2018 |
|---|---|
Revenue/Employee | 66.5m |
Daiichi Sankyo Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Im Co | October 08, 2015 | |
| Rice Force | October 08, 2015 | |
| Ambit Biosciences | September 29, 2014 | $410 m |
| Plexxikon Inc. | April 04, 2011 | $935 m |
| Ranbaxy Laboratories | November 30, 2008 | $4.6 b |
| U3 Pharma AG | May 26, 2008 | |
| Ambit Biosciences Corp. | ||
| American Regent, Inc. | ||
| Daiichi Sankyo | ||
| Daiichi Sankyo Biotech Co., Ltd. |
Daiichi Sankyo Revenue Breakdown
Daiichi Sankyo revenue breakdown by business segment: 92.8% from PHARMACEUTICAL DIVERSIFIED, 7.0% from HEALTHCARE and 0.2% from Other
Daiichi Sankyo Cybersecurity Score
Daiichi Sankyo Environment, Social & Governance (ESG) Ratings
Daiichi Sankyo Online and Social Media Presence
624 Twitter followers
Daiichi Sankyo has 624 Twitter Followers. The number of followers has increased 0.8% month over month and increased 2.2% quarter over quarter
Daiichi Sankyo's Trends
Daiichi Sankyo News and Updates
May 10, 2021
$81 Billion Worldwide Musculoskeletal Disorders Drugs Industry to 2030 - Featuring Pfizer, Abbott Laboratories and Daiichi Sankyo Among Others
Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Musculoskeletal Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information…
May 07, 2021
Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics
DUBLIN, May 7, 2021 /PRNewswire/ -- The "Global Influenza Vaccines Market 2021 - 2027" report has been added to ResearchAndMarkets.com's offering. The number of people being vaccinated with influenza vaccines worldwide will reach 500 million by the year-end of 2027. The Report Analyses...
April 26, 2021
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
– Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments –– Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion –– Demonstrates Daiichi Sankyo Group’s Commitment to the Bempedoic Acid Franchise and Strength of Existing Partnership –…
April 14, 2021
Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal
DUBLIN, April 14, 2021 /PRNewswire/ -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow,...
January 18, 2021
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for …
December 15, 2020
Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that a supplemental application for the antiplatelet agent, prasugrel hydrochloride (hereafter, prasugrel), was filed in Japan to expand the indication for prevention of recurrence of ischemic stroke as a partial change in i…
Daiichi Sankyo Frequently Asked Questions
When was Daiichi Sankyo founded?
Daiichi Sankyo was founded in 2005.
Who are Daiichi Sankyo key executives?
Daiichi Sankyo's key executives are Sunao Manabe, Satoru Kimura and Masahiko Ohtsuki.
How many employees does Daiichi Sankyo have?
Daiichi Sankyo has 16,033 employees.
What is Daiichi Sankyo revenue?
Latest Daiichi Sankyo annual revenue is ¥962.5 b.
What is Daiichi Sankyo revenue per employee?
Latest Daiichi Sankyo revenue per employee is ¥60 m.
Who are Daiichi Sankyo competitors?
Competitors of Daiichi Sankyo include Bayer, Bristol-Myers Squibb and Boehringer Ingelheim.
Where is Daiichi Sankyo headquarters?
Daiichi Sankyo headquarters is located at 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo.
Where are Daiichi Sankyo offices?
Daiichi Sankyo has offices in Tokyo, Chiba, Chiyoda, Chuo City and in 39 other locations.
How many offices does Daiichi Sankyo have?
Daiichi Sankyo has 47 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies